While interest in the psychedelic drug development business is beginning to pick up, one Australia-based advocate said it’s still very early in the country.

In an interview with the Investing News Network (INN) Peter Hunt, chairman of Mind Medicine Australia, shared his expectations for the development of the psychedelics industry in Australia as the sector begins to accelerate in North America.


Mind Medicine Australia, which is not related to the Canadian psychedelics firm Mind Medicine (NEO:MMED), is a research and advocacy non-profit group looking to expand the conversation surrounding this alternative drug opportunity.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Hunt knows a thing or two about investment opportunities having retired in 2018 from a 37 year career in investment banking with Greenhill, which he co-founded.

“We’re all about developing the ecosystem down here so that these medicines can become available to Australians who need them. Irrespective of the wealth of the Australian, savings or whatnot, we want them to be broadly available through the medical system,” he said.

Treating mental health conditions with psychedelics

Hunt is passionate about the opportunity psychedelic medicines offer in treating various mental health conditions, such as depression, anxiety and post-traumatic stress disorder.

Speaking recently at an online seminar designed to give investors a sense of the opportunity attached to psychedelics, Hunt said one in five Australian adults currently faces a chronic mental health illness, representing approximately 4.8 million people.

Hunt told INN he has not seen attacks against the psychedelic drug industry, which has greatly surprised him. Overall, there is much enthusiasm surrounding the potential of these drugs and the investment opportunity attached to the industry.

However, he has seen trepidation attached to a need for more data.

“We always need more research, but the problem is, when you’ve got lots of people suffering … you can keep doing research, but at some stage, you’ve got to say … let’s just start using (psychedelic medicines) in a safe environment with safe protocols and try and help people,” Hunt said.

Australian psychedelics market still young

When it comes to the investment landscape in the Australian psychedelics market compared to the space in Canada, Hunt said Australia still has a long way to go.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“It really is early days, and I think investors are just trying to understand the facts and the data,” he said.

When asked about the potential for a public listing of a psychedelics company in the Australian market, Hunt said it could very well happen before the end of the year.

“It’s probably going to be later this year, or sometime next year,” he said to INN. “I think it’s definitely going to happen.”

Roadblocks attached to research will see a shot in validity once a larger institution, such as a university, becomes a partner attached to a study with these medicines, Hunt said.

While he couldn’t confirm specific details at the time, Hunt said there are advanced discussions between his group and an Australian university to set up an official research partnership, which he said would be a huge boost for the growth of the sector in the country.

“Universities extend knowledge, and I think we’re just touching the surface in terms of just how powerful psychedelic medicine can be across a whole range of mental illnesses,” he said.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less